In the News

Shire Settles Claims Over Alleged ADHD Generic Delay


May 14, 2024

Purchasers of the medication Intuniv have settled a years-old class action against drugmaker Shire PLC and manufacturer Actavis over allegations that the companies struck an anti-competitive deal to delay the production of a generic version of the attention-deficit/hyperactivity disorder drug.

. . .

The class is represented by Lauren G. Barns, Thomas Sobol, Abbye Ognibene, Claudia Morera and Rachel Downey of Hagens Berman Sobol Shapiro LLP, Steve Shadowen, Richard Burnell and Tina Miranda of Hilliard Shadowen LLP, John Radice, Kenneth Pickle, Clark Craddock and April Lambert of Radice Law Firm PC, Joseph Meltzer and Terence Ziegler of Kessler Topaz Meltzer & Check LLP, Sharon Robertson and Donna Evans of Cohen Milstein Sellers & Toll PLLC, Linda Nussbaum and Peter Moran of Nussbaum Law Group PC, Peter Kohn and Joseph Lukens of Faruqi & Faruqi LLP, David Sorensen and Caitlin Coslett of Berger Montague PC, and Joseph Vanek, Paul Slater, David Germaine and John Bjork of Sperling & Slater LLC.

Read Shire Settles Claims Over Alleged ADHD Generic Delay.